文献速递血液净化与透析

肾衰竭患者自报与表现型身体功能测量与死亡率的比较:CONVINCE试验队列分析

Self-Reported Versus Performance-Based Measures of Physical Function and Mortality Among Patients With Kidney Failure: A Cohort Analysis of the CONVINCE Trial.
PubMed 文献 · Am J Kidney Dis · 2026-09-21

本研究基于CONVINCE试验的1360例肾衰竭患者,比较了自报(PROMIS-PF4a)、表现型(PPT)及复合身体功能评分与全因死亡率的关联。中位随访30个月,三种测量均与死亡率独立相关,且区分能力相似(调整C指数约0.71)。自报PROMIS-PF可作为透析常规监测身体功能的实用替代。

要点

  • 自报与表现型身体功能评分均与肾衰竭患者死亡率独立相关。
  • 三种评分的预测区分能力相似,调整C指数约0.71。
  • 严重身体功能受损(T分<30)与显著升高的死亡风险相关。

核心结论

  • 身体功能与肾衰竭患者死亡率强烈且独立相关。
  • 自报PROMIS-PF4a与表现型PPT对死亡率的关联相当。
  • 简短的PROMIS-PF工具可作为表现型评估的实用替代用于常规监测。

研究设计与样本

  • 共纳入1360例患者(女性37.1%,平均年龄62.4岁),中位随访30个月。

主要发现

  • 随访期间266例患者(19.6%)死亡。
  • 调整后每增加1分身体功能评分的风险比:PROMIS-PF4a为0.96(95%CI 0.95-0.98),PPT为0.95(95%CI 0.94-0.97),复合评分为0.96(95%CI 0.94-0.97)。
  • 三种测量的区分能力中等但相似(调整C指数约0.71)。
  • 所有评估类型中,严重身体功能受损(T分<30)与显著更高的死亡风险相关。

关键数值与推荐

  • PROMIS-PF4a、PPT及复合评分每增加1分,调整后死亡风险比分别为0.96、0.95、0.96。
  • 严重身体功能受损定义为T分<30,与 substantially higher mortality risk 相关。

临床怎么用

  • 在透析护理中,可考虑使用简短的PROMIS-PF4a自报问卷常规监测身体功能,作为表现型评估的实用替代。
  • 身体功能评分较低(尤其T分<30)的患者死亡风险较高,需加强关注。

局限性

  • 观察性队列分析基于试验人群,结果推广限于试验参与者和所研究的身体功能工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Physical function (PF) measures derived from patient-reported outcomes (PRO) are simpler to obtain than performance-based outcomes (PerfO), but their relative prognostic value remains unclear. This study compared the associations of these measures with all-cause mortality in patients with kidney failure enrolled in the CONVINCE trial. STUDY DESIGN: Observational multicenter cohort study. SETTING & PARTICIPANTS: Adult patients with kidney failure undergoing high-dose hemodiafiltration or high-flux hemodialysis enrolled in the CONVINCE trial between November 2018 and April 2021. PREDICTORS: Baseline PF scores derived from (1) PRO: the 4-item Patient-Reported Outcomes Measurement Information System (PROMIS) PF short form (PROMIS-PF4a), (2) PerfO: the Physical Performance Test (PPT), and (3) composite PF scores integrating both assessment types. The different PF metrics were standardized to permit comparisons on a common scale. OUTCOME: All-cause mortality over a median follow-up of 30 months. ANALYTICAL APPROACH: Unadjusted and multivariable Cox proportional hazards regression models fitted for each PF predictor. Model discrimination was evaluated using Harrell's C index and time-dependent area under the curve. Restricted cubic splines assessed risk across the PF continuum. Kaplan-Meier curves were stratified according to predefined PROMIS-PF score cut points. RESULTS: Of 1,360 included patients (37.1% women; mean age 62.4 years), 266 patients (19.6%) died during the follow-up period. All 3 PF measures demonstrated statistically significant and comparable associations with mortality in both unadjusted and adjusted analyses. Adjusted hazard ratios per 1-point increase in PF score were 0.96 (95% CI, 0.95-0.98) for PROMIS-PF4a, 0.95 (95% CI, 0.94-0.97) for PPT, and 0.96 (95% CI, 0.94-0.97) for the composite score. Discriminative ability was modest but similar across measures (adjusted C index ≈ 0.71). Across all assessment types, severe PF impairment (T score < 30) was associated with substantially higher mortality risk. LIMITATIONS: Observational cohort analysis of a trial population; generalizability is limited to trial participants and to the examined PF tools. CONCLUSIONS: Physical function was strongly and independently associated with mortality in kidney failure. The patient-reported PROMIS-PF4a and the performance-based PPT demonstrated comparable associations with mortality. These findings support use of the brief PROMIS-PF instrument as a practical alternative to performance-based assessments for routine monitoring of PF in dialysis care.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Brinker AY, Fischer FH, Strippoli GFM, et al. Self-Reported Versus Performance-Based Measures of Physical Function and Mortality Among Patients With Kidney Failure: A Cohort Analysis of the CONVINCE Trial. Am J Kidney Dis. 2026. PMID: 42767323. doi:10.1053/j.ajkd.2026.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。